TGTX Q1 2025 Earnings Call Summary
TGTX reported Q1 2025 earnings with strong performance, including a 137% year-over-year increase in US Net Sales to $119.7 million and a 16% sequential growth. The company raised its full-year 2025 revenue guidance to $560 million from $525 million, with Q2 targeting $135 million. Operating expenses were $82 million, and the company ended the quarter with $276 million in cash and equivalents.
Tickers: $TGTX
Topics: biotech financial performance guidance pharmaceuticals sales growth